Health care stocks were flat to lower pre-bell Monday, with The Health Care Select Sector SPDR Fund (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) inactive.
Revvity (RVTY) shares were down more than 9% after the company reported lower fiscal Q2 adjusted earnings and cut its fiscal 2025 non-GAAP EPS guidance.
Celcuity (CELC) stock was up more than 230% after the company said a phase 3 trial of its drug gedatolisib, combined with fulvestrant, with and without palbociclib, demonstrated a "statistically significant and clinically meaningful" improvement in progression-free survival in a type of breast cancer.
BeOne Medicines (ONC) stock was up more than 2% after the company said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of Tevimbra for treating adults with resectable non-small cell lung cancer at high risk of recurrence.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.